Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has shared an update.
JCR Pharmaceuticals has announced partial corrections to previously disclosed consolidated financial results after identifying double-counted construction-in-progress assets and inventory expenses that had already been recognized. The company plans to file amended securities and semiannual reports with the Kanto Local Finance Bureau in late June 2026 following completion of audit procedures, with the revisions leading to modest improvements in operating profit, ordinary profit, and profit attributable to owners, while leaving net sales unchanged and having only minor effects on total assets and net assets.
The corrections affect the fiscal year ended March 31, 2025 and quarterly results through the nine months ended December 31, 2025, where operating and ordinary profit figures increased slightly and profits attributable to owners rose by up to ¥299 million. These adjustments refine JCR’s reported financial performance without altering its revenue trajectory, suggesting limited operational impact but underscoring the company’s effort to align its financial disclosures with accounting standards and maintain transparency for investors and other stakeholders.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen900.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company focused on developing therapies for rare diseases and other complex healthcare challenges. Based in Japan and listed on the TSE, it markets treatments for growth disorders, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia, while expanding its pipeline and footprint across the U.S., Europe, and Latin America.
Average Trading Volume: 551,901
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen69.05B
For detailed information about 4552 stock, go to TipRanks’ Stock Analysis page.